期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血清IL-8和sApo-1/Fas与乳腺癌患者临床病理学参数的关系 被引量：1

Correlationship between the Serum IL-8 and Soluble Apo-1/Fas and the Clinicopathological Parameters in Patient with Breast Cancer
暂未订购
导出
摘要 目的:探讨外周血IL-8和sFas在不同绝经状态、不同雌激素受体状态(ER)、不同转移情况的乳腺癌术后复发及转移患者中的表达及其临床意义。方法:采用酶联免疫双抗体夹心法检测94例乳腺癌术后复发及转移患者和30例正常人的血清IL-8和sFas水平,并比较它们与绝经状态、ER状态、不同转移情况的关系以及化疗对其影响。结果:1)乳腺癌患者血清IL-8及sFas水平明显高于正常人(P<0.05)。2)血清IL-8与雌激素受体(ER)状态和骨转移关系密切:ER(-)者高于ER(+)者(P<0.05);有骨转移者高于局部复发及/或区域淋巴结转移(P<0.01)以及肝、肺转移者(P<0.05)。3)血清sFas水平与绝经状态及肝、肺转移关系密切:绝经后患者高于绝经前患者(P<0.05);有肝、肺转移者高于局部复发及/或区域淋巴结转移(P<0.01)以及骨转移者(P<0.05)。4)化疗后血清sFas水平较化疗前下降(P<0.05),而血清IL-8无明显变化。结论:血清IL-8和sFas水平与乳腺癌患者的生物学行为及预后有一定关系,值得进一步研究。 Objective： To study the correlationship between the serum IL-8 and soluble Apo-1/Fas and the clinicopathological parameters in postoperative breast cancer patients with recurrent and metastatic foci. Methods： Serum IL-8 and soluble Apo-1/Fas （sFas） was measured by enzyme linked immunosorbent assay （ELISA） in 94 recurrent and metastatic breast cancer patients before and after chemotherapy, as compared with 30 healthy controls. Results： （1） Levels of IL-8 and sFas in breast cancer patients were significantly higher than those in healthy controls （P〈0.05）; （2） Serum IL-8 was correlated with estrogen-receptor （ER） status and bone metastasis： Levels of IL-8 were significantly higher in ER-negative patients compared with ER-positive patients （P〈0.05）, and in patients with bone metastasis compared to patients with local recurrence and/or regional lymph node metastasis （P〈0.01） and patients with liver and/or lung metastasis （P〈0.05）, respectively. （3） Serum sFas was correlated with menopausal status and liver and/or lung metastasis： Levels of sFas were significantly higher in postmenopausal patients compared with premenopausal patients （P〈0.05）, and in patients with liver and/orlung metastasis compared with patients with local recurrence and/or rigional lymph node metastasis （P〈0.01） and patients with bone metastasis （P〈0.05）, respectively. （4） Levels of sFas were remarkably reduced in breast cancer patients after chemotherapy （P〈0.05）, but there is no significant difference in IL-8 level between pretreatment patients and patients after chemotherapy （P 〉 0.05）. Conclusion： Serum IL-8 and sFas are correlated with biological behaviors and prognosis in breast cancer patients and deserve further investigation.
作者 郑天郢 王永刚 张昕
机构地区 山东大学齐鲁医院肿瘤中心化疗科
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2005年第15期864-866,共3页 Chinese Journal of Clinical Oncology
关键词 乳腺肿瘤 IL-8 SAPO-1/FAS Breast neoplasms IL-8 Soluble Apo-1/Fas
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Freund A, Chauveau C, Brouillet JP, et al. IL-8 expression and its relationship with estrogen-receptor-negative status of breast cancer cells[J]. Oncogene, 2003, 22(2):256～265.
  • 2Freund A, Jolivel V, Durand S, et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells [J].Oncogene, 2004, 23(36):6105～6114.
  • 3Lin Y, Huang RH, Chen LP, et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays [J]. Int J Cancer, 2004,109(4):507～515.
  • 4Benoy IH, Salgado R, Van Dam P, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival [J]. Clin Cancer Res,2004, 10(21):7157～7162.
  • 5Bendre MS, Gaddy D, Mon T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo [J]. Cancer Res, 2002, 62(19):5571～5579.
  • 6Bendre MS, Montague DC, Peery T, et al. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease [J]. Bone, 2003,33(1):28～37.
  • 7De Larco JE, Wuertz BR, Manivel JC, et al. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents [J]. Cancer Res, 2001, 61(7):2857～2861.
  • 8Duan Z, Feller AJ, Penson RT, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype[J]. Clin Cancer Res, 1999, 5(11):3445～3453.
  • 9Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients [J]. Clin Cancer Res, 1999, 5(11):3529 ～3533.
  • 10Sheen-Chen SM, Chen HS, Eng HL, et al. Circulating soluble Fas in patients with breast cancer [J]. World J Surg, 2003, 27(1):10 ～ 13.

同被引文献5

  • 1Bennett MW, O' Coneell, O' Sullivan, et al. The Fas counter-attack in vivo apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas Ligand expression by human esophageal carcinoma [ J ]. J I mmunol, 1998,160:5669.
  • 2O' Coneell J, Michael W, Bennett MW, et al. Altered mechanisms of apoptosis in colon cancer: Fas resitance and counterattack in tumor-immune conflict[ J]. Ann NY Acad sci,2000,910:178.
  • 3Elnemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells espress non-functional Fas receptors and conterattack lymphocytes by expressing Fas Ligand : a potential mechanism for immune escape[J]. Int J Oncol,2001,18( 1 ) :33-39.
  • 4Mountz JD, Zhou T, Su X, et al. The role of programmed cell death as emerging new concept for the pathogenesis of autommune disease [J]. Clin Immunol Immunophathol, 1996,80:2-14.
  • 5高德宗,王庆宝,韩国新.大肠癌中Fas、FasL、FAP-1的表达及意义[J].中国癌症杂志,2004,14(2):119-122. 被引量：3

引证文献1

中国肿瘤临床
2005年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部